June 2026 Research Update

Across this group of papers, the main message was that Behcet's disease is diagnosed by recognizing patterns of findings rather than relying on a single definitive test, and that several conditions can resemble Behcet's in specific situations. Evidence ranged from a validated diagnostic scoring system for Behcet's-related eye inflammation to early-stage lab research in saliva and individual case reports showing real-world diagnostic confusion. [1] [2] [3] [4] [5]

For people with uveitis (eye inflammation), a Chinese study created an eye-centered scoring system to help identify Behcet's uveitis by putting more weight on eye findings while still considering key body-wide symptoms. In validation, this Behcet's uveitis scoring approach separated Behcet's uveitis from controls better than two commonly used comparison criteria sets, suggesting that prioritizing eye signs may reduce misclassification in this setting. [1]

For mouth sore conditions that can overlap, a small exploratory study measured many chemicals in saliva and found different overall saliva patterns in Behcet's disease, primary Sjogren's syndrome, and recurrent aphthous stomatitis. In that study, two specific saliva chemicals were higher in the Behcet's group, while other chemicals tended to be higher in the other conditions, showing how a future saliva test might help distinguish similar-looking causes of recurrent sores. [2]

For vascular and lung presentations, a consensus paper proposed preliminary criteria for Hughes-Stovin syndrome, requiring pulmonary artery aneurysms as an entry feature and requiring the absence of uveitis to avoid labeling Behcet's disease as Hughes-Stovin syndrome. The paper also stated that Hughes-Stovin syndrome and Behcet's disease may be considered the same disease with different starting patterns, but it did not recommend using HLA-B51 for diagnosis because it is not specific enough. [4]

Two case reports illustrated diagnostic challenges in specific populations and situations. One report described a 15-year-old girl with fever, genital ulcers, and erythema nodosum where a point-based classification approach supported Behcet's disease after an infection workup did not find a cause, highlighting the complexity of diagnosis in adolescents. [3]

Another report described a man in his 50s whose blood disorder (VEXAS syndrome) caused blood vessel inflammation affecting both arteries and veins and initially looked like Behcet's disease; genetic testing confirmed VEXAS, and ultrasound findings helped clarify the type of temporal vessel inflammation. This single-patient example shows that Behcet's-like symptoms can sometimes come from a different underlying condition, especially when blood counts are severely abnormal. [5]

For patients and caregivers, these papers mainly add background about why diagnosis can take time, especially when symptoms overlap with other ulcer, eye, or blood-vessel conditions. The eye-focused scoring tool is the strongest evidence in this group (a developed and validated clinical tool in one population) and may matter most for people being evaluated for Behcet's-related uveitis, while the saliva metabolite work is early research that still needs larger validation before it can be used in routine care. The case reports and Hughes-Stovin consensus emphasize that certain patterns (such as lung artery aneurysms without uveitis, or a Behcet's-like vasculitis alongside severe low blood counts with a confirming mutation) can point clinicians toward alternative labels, but it remains uncertain how often these scenarios apply across broader patient groups. [1] [2] [3] [4] [5]

Across this group of papers, two messages stood out: (1) several immune-targeting medicines have been reported to control Behcet-related uveitis in many patients, and (2) when looking at all causes of uveitis in clinics, Behcet disease is only one of several common diagnoses and a large share of cases are labeled idiopathic (no clear cause identified). The treatment evidence here is mostly from retrospective data and literature reviews rather than head-to-head randomized trials, and some subtypes of eye disease may respond differently.

In a 64-person real-world retrospective comparison of refractory Behcet uveitis, both tofacitinib and adalimumab were linked with remission and improved vision and eye inflammation measurements over follow-up, with no significant overall differences between groups. In an exploratory subgroup, response looked lower with tofacitinib in people with central occlusive retinal vasculitis (1/7 responders) compared with adalimumab (6/8 responders). [6]

A systematic literature review pooling 92 reported Behcet syndrome patients treated with Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, or upadacitinib) found high remission rates overall (85.9%) and in eye involvement (84.2%). Serious adverse events were reported in 5.4% of patients, and the review reported no blood clot events in these published cases. [7]

One case report described a single 37-year-old man with Behcet disease who had both retinal vasculitis (a Behcet-related problem) and an overlapping outer retina condition described as MORR (within the AZOOR spectrum), documented with repeated imaging. Systemic corticosteroids with cyclosporine appeared to stop rapid worsening, with mostly stable imaging at 3 months and mild progression noted during tapering by 9 months, but this is one person and may not apply to others. [8]

Looking at the broader uveitis population (not only Behcet disease), a 671-patient retrospective study from one Japanese hospital found panuveitis was most common (55.0%) and a definitive diagnosis was made in 62.7% of first-visit patients. Behcet disease accounted for 3.7% of diagnoses, and the authors noted cytomegalovirus (CMV) retinitis and intraocular lymphoma were more common than in earlier nationwide surveys. [9]

A systematic review and meta-analysis of studies from China (2005 to 2025) estimated idiopathic uveitis was the most common category at about 41.8%, followed by Vogt-Koyanagi-Harada (VKH) syndrome (14.1%) and Behcet disease (7.7%), with infectious causes reported less often in the pooled estimates. The authors also emphasized that the proportions varied widely across centers, meaning a persons local setting may look different. [10]

One exploratory lab and animal study focused on why uveitis inflammation may worsen or improve at a biological level. It suggested type III interferon (called IFN-lambda) may help protect the eye by reducing certain immune responses (Th1/Th17) and supporting the retinal barrier, partly through effects on inflammasome pathways in retinal pigment epithelial cells; this is early-stage research rather than a tested treatment in people. [11]

For patients with Behcet disease and uveitis, these papers add context rather than changing care: they summarize that multiple immune-targeting options have been reported to control eye inflammation in many people, but the strongest comparisons here come from retrospective data and published case series, with hints that certain patterns of retinal blood vessel disease may respond differently. The epidemiology studies also show that in general uveitis clinics, many people do not get a single confirmed cause and Behcet disease represents a minority of uveitis diagnoses, which can affect how often clinicians consider different explanations. The biology study is mainly background research that may help explain disease mechanisms, but it does not show a proven new treatment for people yet. [6] [7] [8] [9] [10] [11]

Across three single-patient case reports, Behcet's disease sometimes involved serious blood vessel problems in different organs, including the heart, abdominal veins, and the lungs, and these events required urgent evaluation. The overall pattern was that repeated imaging helped clarify what was happening and track response, while treatment often combined medicines to control inflammation with carefully chosen procedures when the situation was immediately dangerous. [12] [13] [14]

In one pediatric case, a giant aneurysm in the right coronary artery (a heart blood vessel) was first mistaken for a heart mass on early assessment. Because it was considered life-threatening, the 13-year-old boy ultimately underwent coronary artery bypass surgery as part of combined medical and surgical management. [12]

In a 33-year-old woman, Behcet's disease first showed up as a superior mesenteric vein aneurysm (an abdominal vein) with a clot. After treatment with high-dose corticosteroids and cyclophosphamide followed by anticoagulation, serial Doppler ultrasound showed the aneurysm shrinking from 33 mm to 6 mm and partial reopening of the portal vein, although portal venous fibrosis led to plans for infliximab. [13]

In a 20-year-old man, Behcet's disease presented with massive coughing up of blood along with blood clots in multiple locations, including large veins and inside the heart. A step-by-step approach (immediate bleeding control, high-dose corticosteroids, then tailored anticoagulation and biologic immunotherapy) was reported to lead to clinical and imaging improvement with no repeat major bleeding. [14]

For patients and caregivers, these reports are mainly background information that illustrates the range of serious blood vessel complications that can occur in Behcet's disease, and how complex care can become when major organs are involved. Because each paper describes only one person, it is not possible to know how often these events happen or which treatments work best overall, but the cases highlight the role of careful imaging follow-up and coordinated decision-making when aneurysms, clots, or severe bleeding occur. What remains uncertain is how well these approaches apply to other people with Behcet's disease and which parts of the treatment combinations were most important for the outcomes described.

Taken together, these papers suggest two related symptom areas that can affect daily life in Behcet's disease: nervous system symptoms (including brain and blood vessel involvement) and swallowing difficulties. The neurological review highlights that headaches and speech and coordination problems can occur, while the swallowing study suggests many people report symptoms even when food or liquid does not enter the airway during testing. [15] [16]

In a systematic review and meta-analysis focused on North Africa (13 studies; 4,262 people with Behcet's disease), Neuro-Behcet's disease was estimated in 18.54% of patients. Among those with Neuro-Behcet's disease, parenchymal (brain tissue) involvement was more common than non-parenchymal forms, and frequent reported features included pyramidal signs, headaches, dysarthria (speech impairment), and cerebellar signs (balance/coordination problems). [15]

The same review reported that non-parenchymal Neuro-Behcet's disease was mainly vascular, with cerebral venous thrombosis noted as a key pattern, while peripheral neuropathy was uncommon. This supports that Neuro-Behcet's disease can involve both brain tissue and brain blood vessels, with different symptom patterns depending on what is affected. [15]

In a small cross-sectional single-center study of 27 adults, 37.0% reported swallowing symptoms on a questionnaire (EAT-10 score 3 or higher). On an endoscopic swallowing test using only a moderately thick bolus, objective airway invasion was uncommon (PAS 2 or higher in 3.7%), but throat residue was seen more often, especially in the vallecula (18.5%). [16]

For patients and caregivers, this set of studies helps put numbers and symptom examples around two concerns: brain-related symptoms in Behcet's disease (including headache, speech changes, and balance/coordination issues) and swallowing symptoms such as a lump-in-the-throat sensation. The neurological estimates come from pooled North African data and may not match other regions, while the swallowing results come from a small single-center snapshot using one test consistency, so it remains uncertain how often swallowing problems occur across the full range of foods and drinks and over time.

Across these studies, researchers looked for blood-based signals that might reflect overall inflammation, long-term damage, and blood vessel risk in Behcet's disease. One protein marker was higher when disease activity and damage were higher, while lipid (fat) patterns in blood looked different in Behcet's disease and shifted slightly in people with vascular involvement. Overall, the work supports the idea that blood markers may help describe disease burden, but the studies were small and do not show that any single marker can reliably diagnose Behcet's disease or predict what will happen next. [17] [18] [19]

In a 40-person Behcet's disease group compared with 40 healthy controls, the blood protein FSTL1 was higher in Behcet's disease and rose as disease activity and cumulative damage scores increased. When tested as a diagnostic tool, its accuracy was limited, with low sensitivity at the chosen cutoff, meaning many people with Behcet's disease would not be identified by this marker alone. [17]

In a Tunisian case-control study, high-density lipoprotein cholesterol (HDL-C, often called "good cholesterol") was lower in Behcet's disease than in controls. A genetic variant in the endothelial lipase gene (EL 2037 T/C) was not linked to the chance of having Behcet's disease, but in patients it was tied to lower HDL-C in certain situations, including higher homocysteine levels or higher disease activity. [18]

A separate exploratory study used broad lipid profiling (lipidomics) and found many lipid differences between Behcet's disease and healthy controls, showing a clear overall separation between groups. Differences between Behcet's disease with and without vascular involvement were more subtle, with two specific phosphatidylcholine lipids lower and one triacylglycerol lipid higher in the vascular subgroup. Because the vascular subgroup was small and the approach was exploratory, these patterns need confirmation in larger groups. [19]

For patients and caregivers, this body of research mainly adds background about how inflammation and blood vessel-related biology may show up in blood tests, including proteins like FSTL1 and detailed lipid patterns. Right now, these results do not establish a new routine monitoring test, and they do not show that any one marker can replace clinical assessment or reliably forecast future flares or vascular events. Key uncertainties include whether these markers change over time in an individual person, how treatments affect them, and whether they can predict future complications in larger, more diverse patient groups. [17] [18] [19]

This months papers focused on special, higher-risk situations where Behcet's disease overlaps with other major health problems. Overall, the pattern was that outcomes can be severe when Behcet-like intestinal ulcers occur alongside bone marrow disorders that lower blood counts, and that complex surgery may face repeated wound-healing setbacks in some people with Behcet's disease. [20] [21]

In a systematic review pooling 128 reported patients with intestinal ulcers and low blood counts in the setting of intestinal Behcet's disease or inflammatory bowel disease plus myelodysplastic syndrome (a bone marrow disorder) or aplastic anemia, overall mortality was substantial at 34.9% among those with available data. Different subgroups had different patterns, including a high frequency of trisomy 8 in Behcet's disease with myelodysplastic syndrome, and higher-risk myelodysplastic syndrome types were linked to higher mortality in inflammatory bowel disease with myelodysplastic syndrome. [20]

The same pooled analysis reported that no single treatment approach showed a statistically significant survival benefit in the authors univariable analyses, and the literature often lacked consistent reporting of side effects. Because most included publications were case reports or small case series, the review could not firmly determine which factors cause better or worse outcomes. [20]

A separate case report described one 51-year-old woman with Behcet's disease who had repeated wound breakdown after major oral cavity cancer surgery and reconstruction, including tissue necrosis and wound opening at both the mouth and donor site. She required multiple steps such as tissue removal, negative-pressure wound therapy, skin grafting, and later a salvage reconstruction flap, and her radiotherapy was delayed due to a persistent fistula. [21]

For patients and caregivers, these reports mainly add background about uncommon but high-complexity situations: (1) intestinal ulcers with very low blood counts when Behcet's disease (or similar bowel inflammation) overlaps with bone marrow disorders, and (2) difficult wound healing after extensive surgery. The strongest signals here are about risk and uncertainty rather than clear best next steps, because much of the evidence comes from pooled case reports and a single-patient report, with incomplete data on side effects and limited ability to compare treatments. [20] [21]

Two studies looked at the wider context around Behcet's disease: how often Behcet's disease appears alongside other inflammatory illnesses in population data, and how much Behcet's disease is represented in the fast-growing artificial intelligence (AI) rheumatology research literature. Together, they suggest both real-world overlap with other immune conditions and a research gap in newer AI-focused work. [22] [23]

In a nationwide retrospective matched-cohort study from Israel, people with familial Mediterranean fever (FMF) had a higher baseline prevalence of several rheumatologic conditions, including Behcet disease, compared with matched controls. Over long-term follow-up, FMF was linked to higher incidence of multiple autoimmune diseases, and amyloidosis was much more frequent in FMF than in controls. [22]

In a bibliometric analysis of 1,057 Scopus-indexed publications on AI in rheumatology, publication volume rose sharply after 2018, but the most common disease topics were osteoarthritis and rheumatoid arthritis. Behcet disease appeared far less often than these leading topics, and the authors also noted two retracted AI-rheumatology papers due to peer-review irregularities, highlighting the need for strong research standards. [23]

For patients, the FMF study is most relevant as population-level context: it suggests that some inflammatory diseases can cluster together over time in real-world health records, including overlap involving Behcet's disease and rare complications like amyloidosis in FMF. The AI bibliometric study does not change care, but it helps explain why AI tools or studies may feel more developed in common arthritis conditions than in Behcet's disease, and it underscores that research quality checks matter as the field grows. [22] [23]